Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.47% | -4.10% | 5.59% | -12.50% | -19.49% |
| Total Depreciation and Amortization | -7.50% | 16.70% | -1.78% | 5.53% | 3.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.47% | 43.44% | -1.05% | -10.66% | 31.24% |
| Change in Net Operating Assets | 107.82% | -382.58% | 720.20% | -122.64% | 169.23% |
| Cash from Operations | 24.47% | -34.23% | 16.09% | -28.97% | 2.94% |
| Capital Expenditure | 36.46% | -79.04% | 46.93% | 73.05% | -158.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 110.66% | -536.97% | -65.25% | 302.56% | 148.58% |
| Cash from Investing | 110.42% | -541.91% | -65.35% | 334.24% | 144.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.71% | 1,399.72% | 744.20% | -56.29% | 59.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -97.71% | 1,397.50% | 744.20% | -56.29% | 59.00% |
| Foreign Exchange rate Adjustments | 1,750.00% | 92.45% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -559.53% | 229.80% | -117.25% | 239.99% | 75.97% |